



June 9, 2026

The Honorable Brett Guthrie
Chairman, Committee on Energy and Commerce
U.S. House of Representatives
2125 Rayburn House Office Building
Washington, DC 20515

The Honorable Frank Pallone, Jr.
Ranking Member, Committee on Energy and
Commerce
U.S. House of Representatives
2323 Rayburn House Office Building
Washington, DC 20515

Dear Chairman Guthrie and Ranking Member Pallone:

On behalf of the Council of State Bioscience Associations (CSBA), we write to express our support of the SECURE Data Act (H.R. 8413). The CSBA is a coalition of state and territory-based life sciences trade associations that advocate for public policies to support development and delivery of innovative medicines. The collective CSBA voice represents a nationwide grassroots network of innovators, researchers, manufacturers, and accelerators. Our member companies employ 2.3 million people in more than 149,000 businesses across the U.S. and Puerto Rico. The total economic impact of the bioscience industry on the U.S. economy totaled \$3.2 trillion dollars in 2023.¹

Our members are research-intensive life sciences companies working to bring cutting-edge biomedical therapies to market. A key factor in bringing safe and effective therapies to market is the ability of our companies to ethically collect, store, and use biomedical data. Unfortunately, the current patchwork of state data privacy laws, federal regulations, and varying privacy rules result in increased regulatory burden and confusion, which hinders the lifesaving biomedical research and development that brings medicines to patients.

The CSBA supports a strong preemptive framework that protects consumers while providing regulatory certainty and predictability regarding the collection, use, and sharing of scientific and biomedical data. We also maintain that any national privacy framework must recognize existing federal regulations governing the handling of clinical research data by the U.S. Food and Drug Administration (FDA) and through the Health Insurance Portability and Accountability Act (HIPAA). These laws have successfully balanced appropriate use of clinical and scientific research and critical patient privacy protections regarding their health.

¹ TEconomy/Biotechnology Innovation Organization. (2024). *The U.S. Bioscience Economy: Driving Economic Growth and Opportunity in States and Regions*. <https://www.bio.org/csba-resources-and-reports>

These principles are firmly outlined in the SECURE Data Act, and CSBA writes to endorse the Biotechnology Innovation Organization's (BIO) letter of support for this legislation and specifically these provisions. We ask that you maintain and strengthen these policies as you move forward throughout the legislative process.

We look forward to continuing to work with Congress to chart a path forward on these important patient protections. Should you have any questions, please contact our CSBA Board Chair Mike Guerra at mguerra@califesciences.org.

Sincerely,

Mike Guerra
Chair, Council of State Bioscience Associations
President & CEO, California Life Sciences

Jennifer Hawks Bland
Vice Chair, Council of State Bioscience Associations
CEO, NewYorkBIO

John Conrad
CEO, Illinois Biotechnology Innovation Organization

Kelvyn Cullimore
President & CEO, BioUtah

Joni Ekstrum
CEO, South Dakota Bio

Maria Thacker Goethe
CEO, Georgia Life Sciences

Laura Gunter
President & CEO, North Carolina Life Sciences
Organization

John Newby
President & CEO, Virginia Bio

Rob Owen
Executive Director, Bio Nebraska